# Using next generation matrices to estimate the proportion of infections

## that are not detected in an outbreak

- H Juliette T Unwin<sup>1,\*</sup>, Anne Cori<sup>1</sup>, Natsuko Imai<sup>1</sup>, Katy A. M. Gaythorpe<sup>1</sup>, Sangeeta Bhatia<sup>1</sup>, Lorenzo Cattarino<sup>1</sup>, Christl A. Donnelly<sup>1,2</sup>, Neil M. Ferguson<sup>1</sup> and Marc
- Baguelin<sup>1,3</sup>

10

13 14

22

25

- 1) MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London.
  - 2) Department of Statistics, University of Oxford
    - 3) Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
- \* Corresponding author: H Juliette T Unwin, PhD, h.unwin@imperial.ac.uk, +44 (0)20 7594 3660 12
- Acknowledgments: All authors acknowledge funding from the MRC Centre for Global Infectious 15
- Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council 16
- (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the 17
- MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the 18
- European Union; and acknowledge funding by Community Jameel. HJTU also acknowledges 19
- funding from Imperial College, London for her fellowship. CAD also acknowledge the NIHR 20
- 21 Health Protection Research Unit in Emerging and Zoonotic Infections.
- Data availability: All code necessary to implement the analysis is included open source in the 23
- "MissingCases" R package on GitHub https://github.com/mrc-ide/MissingCases. 24
- Competing interests: None 26
- Author contributions: Marc Baguelin, Anne Cori, Neil M. Ferguson and H. Juliette T. Unwin 28
- designed the study, H. Juliette T. Unwin implemented the initial analysis and Marc Baguelin 29
- oversaw the study. Natsuko Imai, Katy A. M. Gaythorpe, Sangeeta Bhatia, Lorenzo Cattarino and 30
- Christl A. Donnelly contributed to discussion of the results and conclusions. 31

Contact tracing, where exposed individuals are followed up to break ongoing transmission 32 chains, is a key pillar of outbreak response for infectious disease outbreaks. Unfortunately, 33 these systems are not fully effective, and infections can still go undetected as people may 34 not remember all their contacts or contacts may not be traced successfully. A large 35 proportion of undetected infections suggests poor contact tracing and surveillance systems, 36 which could be a potential area of improvement for a disease response. In this paper, we 37 present a method for estimating the proportion of infections that are not detected during an 38 outbreak. Our method uses next generation matrices that are parameterized by linked 39 contact tracing data and case line-lists. We validate the method using simulated data from 40 an individual-based model and then investigate two case studies: the proportion of 41 undetected infections in the SARS-CoV-2 outbreak in New Zealand during 2020 and the 42 Ebola epidemic in Guinea during 2014. We estimate that only 5.26% of SARS-CoV-2 43 infections were not detected in New Zealand during 2020 (95% credible interval: 0.243 – 44 16.0%) but depending on assumptions 39.0% or 37.7% of Ebola infections were not 45 detected in Guinea (95% credible intervals: 1.69 - 87.0% or 1.7 - 80.9%). 46 47 48 49 50

#### INTRODUCTION

52

There are many non-pharmaceutical interventions for controlling infectious disease 53 epidemics. Some control measures, such as case isolation and safe and dignified burials 54 avoid secondary infections but others, such as contact tracing, avoid tertiary infections. 55 Measures, which avoid secondary infections, are most effective when tertiary infections are 56 also avoided and all (or nearly all) infections are identified so that interventions can be 57 targeted (1). If contact tracing is implemented well, contacts of known cases can take 58 precautions to reduce onward transmission by limiting their contacts and isolating quickly 59 on symptom onset (2–4). However, if many infections are not detected, outbreaks can 60 grow rapidly as undetected infections usually infect more people than detected cases (5). 61 Infections or deaths may not be reported for a variety of reasons (6). Poor availability of 62 tests at the start of an outbreak of an emerging pathogen, such as SARS-CoV-2, may mean 63 that those with symptoms cannot be diagnosed (7). Asymptomatic individuals may also not 64 know they are infected unless tested for other reasons, such as through contact tracing (8). 65 Undetected infections are not unique to SARS-CoV-2 and under-reporting is common in 66 Ebola outbreaks due to barriers to accessing health care and limited hospital capacity (9). 67 Many patients may not seek health care due to mistrust and if they die, may be buried 68 without notification, leading again to those cases being missed from official lists (10). 69 Infectious disease analysis and modelling are important tools for managing epidemics and 70 can help provide quantitative evidence and situational awareness to public health responses 71 (11). The importance of such analyses has been highlighted by the response to the COVID-72

19 pandemic, which has been, to a large extent, informed by epidemic modelling e.g. (12– 73 14). However, these models often require robust case data to make accurate transmission 74 predictions. Over time attempts have been made to account for under-reporting in models. 75 Some models assume perfect reporting (15,16), however, this can lead to an underestimation of the infection rate (6). Other methods assume a constant under-reporting 77 rate (17), use data augmentation techniques (6) or rely on more complex models to merge 78 multiple data streams through evidence synthesis (18). More recently, many models have 79 switched to using death data, which was believed to be more reliable than case data, 80 because it is more likely consistent over time and between countries (13). This is especially 81 important for methods which are robust to constant under-reporting. 82 We propose using a quasi-Bayesian next generation matrix (NGM) approach in this paper 83 to estimate the proportion of infections that are not detected in an outbreak. This method is 84 not disease specific, is simple to implement from contact tracing and surveillance data and 85 can be repeated throughout the outbreak to provide time varying estimates. We investigate 86 the suitability of our method using simulated data and present two applications of our 87 method: the SARS-CoV-2 outbreak in New Zealand (NZ) in 2020 and the Ebola epidemic 88 in Guinea in 2014. 89 **METHODS** 90 NGMs are often used to calculate the basic reproduction number (the average number of 91 secondary infections generated by a primary infection in a large fully susceptible 92 population),  $R_0$ , from a finite number of discrete categories that are based on 93

epidemiologically relevant traits in the population, such as infected individuals at different 94 stages of infection (e.g. exposed and infectious) or with different characteristics (e.g. age) 95 e.g. Baguelin et al. (19). The NGM is a matrix which quantifies the number of secondary 96 infections generated in each category by an infected individual in a given category.  $R_0$  is 97 defined as the dominant eigenvalue of this matrix (20,21). They have also been used by 98 Grantz et al. (22) to evaluate contact tracing systems. Similarly, here we stratify infected 99 individuals using information about their contact tracing status and whether they were 100 being followed up at the time of symptom onset to assign infection pathways and construct 101 our NGM. We identify three types of infections: i) infections that are not detected (ND), ii) 102 infections (or cases) that are detected but not under active surveillance (NAS), and (iii) 103 infections (or cases) that are detected and under active surveillance (AS). 104 Contact follow-up or surveillance might take different forms for different diseases; for 105 Ebola, a contact under active surveillance would be undergoing in-person follow-up for 21 106 days after their last interaction with the case (23), whereas for SARS-CoV-2 in some 107 settings, a contact under active surveillance may be notified by contact tracers, or through a 108 mobile phone application, and asked to self-isolate for up to 10 days (24,25). 109 Formulation of the NGM 110 For contact tracing to be fully effective, the parent (or primary) case needs to be diagnosed 111 and, if positive, all their contacts placed under active surveillance. The parent case 112 therefore needs to know and remember everyone they have been in close contact with 113 whilst they have been infectious and for these contacts to be contacted. Despite a contact

being recalled and reported, they may not be under active surveillance if they cannot be identified due to missing or incorrect contact details or evasion from contact tracers. We assume in our model that: i) infections that are not detected and those cases detected but not under active surveillance have the same effective reproduction number (R) and therefore on average, infect the same number of secondary cases; and ii) AS have a lower effective reproduction number (scaled by  $\alpha$ ) because they are rapidly isolated after the onset of symptoms. We define  $\phi$  as the proportion of contacts recalled,  $\gamma$  as the proportion of contacts actively under surveillance, and  $\pi$  as the proportion of cases detected or "recaptured" by community surveillance.

115

116

117

118

119

120

121

122

- We identify 12 pathways through which individuals can become infected (Figure 1). These pathways are described as follows:
- 126 1. A case that was detected (with probability  $\pi$ ), who was infected by an infection that

  was not detected and was therefore not under active surveillance.
- 2. An infection that was not detected (with probability  $1-\pi$ ), who was infected by an infection that was not detected and was therefore not under active surveillance.
- 3. A case that was detected (with probability  $\pi$ ), who was infected by a case that was detected but not under surveillance, was correctly recalled as a contact (with probability  $\phi$ ) and was under active surveillance (with probability  $\gamma$ ).
- 4. A case that was detected (with probability  $\pi$ ), who was infected by a case that was detected but that was not under surveillance, was correctly recalled as a contact (with probability  $\phi$ ) but was not under surveillance (with probability 1-  $\gamma$ ).

- 5. An infection that was not detected (with probability 1- $\pi$ ), who was infected by a case that was detected but not under surveillance, was correctly recalled (with probability  $\phi$ ) but was not under surveillance (with probability 1- $\gamma$ ).
- 6. A case that was detected (with probability  $\pi$ ) case, who was infected by a case that was detected but not under surveillance, that was not recalled (probability 1- $\phi$ ).
- 7. An infection that was not detected (with probability  $1-\pi$ ) case, who was infected by a case that was detected but not under surveillance, that was not recalled (probability  $1-\phi$ ).
- 144 8. A case that was detected (with probability  $\pi$ ), who was infected by a case that was
  145 detected and under surveillance, was correctly recalled (with probability  $\phi$ ) and was
  146 under surveillance (with probability  $\gamma$ ).
- 9. A case that was detected (with probability  $\pi$ ) case, who was infected by a case that was detected and under surveillance, was correctly recalled (with probability  $\phi$ ) but was not under surveillance (with probability 1-  $\gamma$ ).
- 150 10. An infection that was not detected (with probability 1- $\pi$ ), who was infected by a case that was detected and under surveillance, was correctly recalled (with probability  $\phi$ ) but was not under surveillance (with probability 1- $\gamma$ ).
- 153 11. A case that was detected (with probability  $\pi$ ), who was infected by a case that was detected and under surveillance, that was not recalled (with probability 1- $\phi$ ).

12. An infection that was not detected (with probability  $1-\pi$ ) case, who was infected by a case that was detected and under surveillance, that was not recalled (with probability 156  $1-\phi$ ).

155

157

Seven of our twelve pathways result in detected cases. The cases from pathways 3, 4, 8, and 158 9 are individuals on contact lists who are detected as cases whereas, the cases from 159 pathways 1, 6, and 11 are de novo cases that are not on any contact tracing list, but which 160 are detected via other routes such as attending a health care unit. The cases from pathways 161 3 and 8 are contacts who were under surveillance at the time of symptom onset, while those 162 from pathways 4 and 9 were not under surveillance at onset. The infections resulting from 163 the pathways 2, 5, 7, 10 and 12 are not detected by the surveillance system. We use the 164 notation  $F_X$  to denote the likelihood of a case stemming from pathway X, for example  $F_1$ 165 equals  $R\pi$ . 166

If  $Z_n = [ND_n, NAS_n, AS_n]^T$  is a vector of the number of each type of case for generation n, 167 the dynamics of the model is given by: 168

$$Z_{n+1} = AZ_n \ (1)$$

where A is our NGM that represent the potential transitions from one generation of cases to 169 the next 170

$$A = R \begin{bmatrix} 1 - \pi & (1 - \pi)(1 - \gamma\phi) & \alpha(1 - \pi)(1 - \gamma\phi) \\ \pi & \pi(1 - \gamma\phi) & \alpha\pi(1 - \gamma\phi) \\ 0 & \gamma\phi & \alpha\gamma\phi \end{bmatrix}. (2)$$

From the eigenvalues of this NGM, we can calculate the proportion of each of the three 171 types of infections (ND, NAS and AS), see Supplementary Information (SI) A. In the limit 172 as n goes to infinity, an equilibrium is reached and the proportion of cases that are not 173 detected,  $\mu_{ND}$ , can be calculated as: 174

$$\mu_{ND} = \lim_{n \to \infty} \frac{ND_n}{ND_n + NAS_n + AS_n}$$

$$= \frac{(-1 + \pi)(1 + \alpha(-2 + \gamma\phi) - \pi\gamma\phi + \sqrt{-2\pi(1 + \alpha(-2 + \gamma\phi))\gamma\phi + \pi^2\gamma\phi}]^2 + (-1 + \alpha\gamma\phi)^2)}{2(\alpha - 1)}.$$
(3)

As shown in the calculation in the SI and illustrated Figure S1 in SIA, convergence to this 175 equilibrium value is fast. 176

Linking our model to contact tracing and surveillance system data 177

185

187

Cases are often recorded in line-lists during disease outbreaks, where dates of testing, 178 symptom onset and hospitalization are recorded alongside information about the age and 179 sex of the patient. When case lists are linked to contact lists, we can derive two ratios with 180 which we parameterize our NGM. We define  $r_1$  as the ratio of cases who were contacts but 181 not under surveillance versus the cases who were contacts and under surveillance and  $r_2$  as 182 the ratio of de novo cases (cases that were not known contacts) versus detected cases that 183 were contacts and under surveillance. 184

Following the pathways in Figure 1, we expand  $r_1$  (the ratio of cases who were contacts but not under surveillance versus the cases who were contacts and under surveillance) as 186  $\left|\frac{F_4+F_9}{F_0+F_0}\right|$ . At the equilibrium of the surveillance process (SIA), we have  $ND_n=\mu_{ND}C_n$ ,

 $NAS_n = \mu_{NAS}C_n$  and  $AS_n = \mu_{AS}C_n$ , where  $C_n = ND_n + NAS_n + AS_n$  is the total number of cases at generation n,  $\mu_{NAS}$  is the proportion of cases not under active surveillance and  $\mu_{AS}$  is the proportion of cases under active surveillance. Therefore,

$$r_{1} = \frac{R\phi\pi(1-\gamma)\mu_{NAS}S_{n} + \alpha R\phi\pi(1-\gamma)\mu_{AS}S_{n}}{R\phi\gamma\mu_{NAS}S_{n} + \alpha R\phi\gamma\mu_{AS}S_{n}}$$
$$= \frac{(1-\gamma)\pi}{\gamma}.$$
 (4)

We re-write this as

$$\gamma = \frac{\pi}{r_1 + \pi}. \quad (5)$$

We also expand  $r_2$  (the ratio of de novo cases versus detected cases that were contacts and

under surveillance) as  $\left[\frac{F_1+F_6+F_{11}}{F_3+F_8}\right]$ . Therefore,

$$r_{2} = \frac{R\pi(\mu_{ND}S_{n} + (1 - \phi)\mu_{NAS}S_{n} + \alpha(1 - \phi)\mu_{AS}S_{n})}{R(\phi\gamma\mu_{NAS}S_{n} + \alpha\phi\gamma\mu_{AS}S_{n})}$$

$$= \frac{\pi(\beta + (1 - \phi))}{\phi\gamma},$$
(6)

where  $\beta = \frac{\mu_{ND}}{\mu_{NAS} + \alpha \mu_{AS}}$ . This can be rewritten as

$$\mu_{ND} = \nu(\mu_{NAS} + \alpha \mu_{AS}), \ \nu = \frac{r_2 \phi \gamma}{\pi} - 1 + \phi.$$
 (7)

Figure 2 illustrates the dependencies between these two ratios and the parameters in our model in a directed acyclic graph where the green nodes are our data, blue nodes are model parameters and white nodes are calculated parameters.

198

199

200

201

202

203

210

213

In addition to equations (5) and (7), we also have three more relationships that we can use: the proportions of each type of case ( $\mu_{ND}$ ,  $\mu_{NAS}$  and  $\mu_{AS}$ ) that are found using the leading eigenvector of the NGM (see SIA). We therefore have five equations and seven unknown parameters ( $\pi$ ,  $\alpha$ ,  $\phi$ ,  $\gamma$ ,  $\mu_{ND}$ ,  $\mu_{NAS}$ ,  $\mu_{AS}$ ). If we fix two parameters, we can then estimate the other parameters. We choose here to fix  $\alpha$  since this could be estimated from additional data such as serology and  $\pi$ .

Application to the estimation of the proportion of infections that were not detected

We estimated the proportion of infections that are not detected using a quasi-Bayesian

framework for each scenario. For each run of each scenario, we sampled 10,000 values

from  $[0,1]^2$  uniformly for  $(\pi,\alpha)$ , which is comparable to assuming a uniform prior

distribution, and computed the other parameters  $(\gamma,\phi,\mu_{ND})$  if a solution was viable. We

note that there is no solution for some values of  $(\pi,\alpha)$ , (see SIB). Our credible intervals

211 Simulated data. We investigate the suitability of our method using an individual-based 212 model developed using NetLogo(26) (see SIC) for 3 scenarios:

(CrI) reflect the values between which 95% of our viable samples lie.

1) Contact tracing similar to SARS-CoV-2 example in New Zealand (NZ);

2) Contract tracing similar to Ebola in Guinea;

215 3) Contact tracing similar to Ebola in Guinea and then improves to match the SARS 216 CoV-2 example in NZ after 500 days.

For each scenario, we simulated 1000 runs and sampled each run 10,000 times. Here we assumed prior knowledge about the values of  $\pi$  and  $\alpha$  so uniformly sampled between 0.2 above and below the true values of  $\pi$  and  $\alpha$  (see SIC for parameter value). We compared the probability that the true parameters in each of our scenarios lie within the 95% CrI estimates. We consider two time periods for scenario 3, before and after the parameter change.

We also undertook a sensitivity analysis to investigate relaxing our assumption on  $\alpha$ , where we compared the estimated values of missing cases when we varied the reduction in the scaling for a NAS case. We compared the probability that the true value of the proportion of infections that were not detected lies within our 95% CrI for scenario one with values of alpha for NAS cases of 0.6 and 0.8 and 1.0 (initial scenario one). We again ran 1000 simulations of each and assumed the parameter were equal to the SARS-CoV-2 scenario.

*SARS-CoV-2 in New Zealand 2020.* Well performing contact tracing systems have been partially credited for the success of NZ's response to the SARS-CoV-2 epidemic in 2020 (27–29). NZ's Ministry of Health reported 570 locally acquired cases up until 14<sup>th</sup> December 2020 that had an epidemiological link to a previous case and 90 cases without an epidemiological link (30). We assume that 80% of contacts were under active surveillance

before diagnosis, since 80% was determined as the minimum requirement for the NZ 234 system (25). Therefore, we estimate 456 cases were under active surveillance and 114 235 cases were not. This makes  $r_1 = 0.25$  and  $r_2 = 0.20$ . 236 Ebola in Guinea 2014 We use data from Dixon et al. (31), which present contact tracing 237 outcomes from two prefectures in Guinea between the 20th September and 31st December 238 2014. The authors found that only 45 cases out of 152 were registered as contacts of known 239 cases across Kindia and Faranah prefectures. 240 Since there is little published data, we consider two scenarios based on different 241 assumptions about  $r_1$  (ratio of contacts not under active surveillance versus contacts under 242

active surveillance).

243

244

245

246

247

248

249

250

251

252

1) We assume  $r_1$  is equal to 0.2 (five times as many contacts under active surveillance than not under active surveillance, or 5 out of 6 contacts are under active surveillance). This is based on data from Liberia in 2014 and 2015 where, during the same epidemic as Guinea, 27936 contacts were not under active surveillance, whereas 167419 were (32). Since we know the total number of cases on the contact tracing list, 45, and assume  $r_1 = 0.2$ , we estimate the number of contacts under active surveillance to be 38 (denominator of  $r_2$ ). The number of people not on the contact list for the two regions was 107 (numerator of  $r_2$ ). Therefore,  $r_2$  is equal to 2.85.

2) We assume  $r_1$  is equal to 0.5 (twice as many contacts under active surveillance than not under active surveillance or two thirds of contacts are under active surveillance) to illustrate the impact of a slightly better surveillance system. Since we know the total number of cases on the contact tracing list, 45, and assume  $r_1 = 0.5$ , we estimate the number of contacts under active surveillance to be 30 (denominator of  $r_2$ ). Therefore,  $r_2$  is equal to 3.57.

We again estimated the proportion of infections that are not detected using our quasi-Bayesian framework for both case studies and took 100,000 samples for each case study, sampling  $\pi$  and  $\alpha$  between 0 and 1. All code necessary to implement the analysis is included open source in the "Missing Cases" R package on GitHub (33).

### RESULTS

Simulated data. We find that in our three scenarios, the true proportion of infections that are not detected always lie within the uncertainty intervals of the NGM estimates even in scenario 3 where our parameters are not constant. We note this method performs best early in the outbreak when the number of susceptible are large and not in the tail end of the outbreak. However, not all parameters perform consistently well as shown in Table S2, where  $\gamma$  only lies within the interval 75.4% of the time in scenario 1 and  $\phi$  only 24.6% of the time in scenario 2. We found that performance remained similar if we reduced alpha for NAS cases (Table S3).

SARS-CoV-2 in New Zealand 2020. We estimate that only 5.26% (95% CrI: 0.245 - 16.0%) 272 of cases were not detected during this wave of the SARS-CoV-2 pandemic in NZ (see 273 Table 1 for all parameter estimates), which suggests a well-functioning and rigorous 274 contact tracing and surveillance system in NZ. In Figure 3, we find that this estimate comes 275 from a feasible parameter space that is focused along the right-hand side of the parameter 276 space, where the proportion of cases detected in the community  $(\pi)$  is high. However, we 277 do not learn anything about the scaling in transmission for traced cases so the uncertainty 278 intervals in the proportion of not detected infections account for this. 279 Ebola in Guinea 2014. We estimate that the proportion of Ebola cases that were not 280 detected in Guinea was 39.0% (95% CrI: 1.69-87.0%) or 37.7% (95% CrI 1.70 – 80.9%) 281 for our two scenarios where  $r_1 = 0.2$  and  $r_1 = 0.5$  respectively. The corresponding model 282 parameter estimates for both scenarios are given in Table 2. The only parameter that differs 283 substantially between our scenario is the proportion of contacts under active surveillance, 284 which is directly impacted by the ratio of contacts not under active surveillance versus 285 contacts under active surveillance. We find that we do not learn much about the feasible 286 values of  $\alpha$  and  $\pi$  for these scenarios but as proportions of cases detected in the community 287 fall, the proportion of not detected infections increases. 288 DISCUSSION 289 Contact tracing is an important control mechanism for infectious disease outbreaks. 290 However, its efficiency depends on detecting as many cases as possible. We show in this 291 paper that NGMs can be easily used to estimate the proportion of cases that were not 292

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

detected in simulated examples and two different disease outbreaks. Our method requires much less data to parameterize our model that other methods, such as capture re-capture (10), which is an alternative method suggested for estimating under-reporting and is highly data intensive. This means that it is feasible to repeat this analysis in near real time as the epidemic unfolds. We find that in our time varying simulation (scenario 3) 95.4% of the simulated proportion of infections not detected lie within the 95% credible intervals but there is a slight bias in the "transient phase" (group 3) where the NGM estimates are higher than the true estimates. This could be because equilibrium had not been reached. During the West African Ebola epidemic, the WHO acknowledged that their reported case and death figures "vastly underestimate(d)" the true magnitude of the epidemic (34). We find that our estimates for the proportion of cases not detected in Guinea (39.0% (95% CrI: 1.69-87.0%) or 37.7% (95% CrI 1.7 – 80.9%) for our two scenarios where  $r_1 = 0.2$  and  $r_1 = 0.5$  respectively) are in line with values in the literature for neighbouring countries. Dalziel et al. (9) suggested reporting rates in Sierra Leone of 68% (32% under reporting) in the Western Area Urban on 20 October 2014 using burial data. However, higher under reporting has also been estimated: the US Centers for Disease Control and Prevention (35) estimated a 40% reporting rate (60% under-reporting) from Ebola treatment unit bed data and Gignoux et al. (36) estimated a 33% (67% under-reporting) from a capture and recapture study in Liberia between June and August 2014. Our estimates of the proportion of cases that were not detected during the SARS-Cov-2 outbreak in NZ of 5.26% (95% CrI 0.243 - 16.0%) is in-line with the good health care

facilities and the low community transmission of SARS-CoV-2 in NZ (30), but we did not 314 find any estimates in literature to compare our estimates to. 315 A benefit of this method is that we do not just estimate the proportion of cases that were not 316 detected but also other useful quantities that are important for managing a response such as 317 the proportion of contacts recalled and under surveillance. The wide CrI, especially in 318 second and third simulated data scenarios and the Ebola case study, come from the uniform 319 sample of  $(\pi, \alpha)$ . This is a limitation of the method but could be improved with better 320 understanding of the performance of the routine surveillance  $(\pi)$  and changes in 321 transmissibility due to contact tracing status ( $\alpha$ ), which would narrow the region in the 322 parameter space. A second limitation is our assumption on  $\alpha$  that only detected cases under 323 active surveillance have a reduced transmissibility. In this simple framework, it is not 324 possible to relax this assumption; however if additional information such as serology was 325 available, we believe this could be used to form a prior distribution on this parameter and 326 potentially allow users to further vary the number of people NAS and ND individuals infect 327 or improve the accuracy of some of the other parameter estimates. As we see in our 328 sensitivity analysis, this does not impact our estimation of the proportion of infections that 329 were not detected but potentially other parameters. A third limitation is that we do not 330 account for differing times to locate contacts within each group, which would further vary 331 the number of cases each case goes on to infect. 332 We believe this method highlights important lessons for responding to the ongoing SARS-333

CoV-2 pandemic and the unfortunate inevitability of future infectious disease outbreaks. By

method from our "MissingCases" package (33) to assess under-reporting throughout an epidemic. This would help outbreak responses, especially during the early and late phases, target resources and quantify how effect their surveillance systems were. In addition, these estimates can be used to improve the accuracy of other models, such as for the time varying reproduction number, which are key tools for the outbreak response themselves.

#### REFERENCES

335

336

337

338

339

340

341

342

355

- 1. Salathé M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J, et al. COVID19 epidemic in Switzerland: On the importance of testing, contact tracing and
  isolation. Swiss Med Wkly [Internet]. 2020 Mar 19 [cited 2020 Dec 10];150(11–12).

  Available from: https://doi.emh.ch/smw.2020.20225
- 2. Saurabh S, Prateek S. Role of contact tracing in containing the 2014 Ebola outbreak:
  a review. Afr Health Sci [Internet]. 2017 Mar [cited 2020 Dec 10];17(1):225–36.

  Available from: http://www.ncbi.nlm.nih.gov/pubmed/29026397
- 350 3. Lópaz MA, Amela C, Ordobas M, Domínguez-Berjón MF, Álvarez C, Martínez M,
  351 et al. First secondary case of Ebola outside Africa: epidemiological characteristics
  352 and contact monitoring, Spain, September to November 2014. Eurosurveillance
  353 [Internet]. 2015 Jan 8 [cited 2020 Dec 10];20(1):21003. Available from:
  354 https://www.eurosurveillance.org/content/10.2807/1560-7917.ES2015.20.1.21003
  - 4. Smith CL, Hughes SM, Karwowski MP, Chevalier MS, Hall E, Joyner SN, et al.

    Addressing needs of contacts of Ebola patients during an investigation of an Ebola

- cluster in the United States Dallas, Texas, 2014. [Internet]. Vol. 64, MMWR.
- Morbidity and mortality weekly report. 2015 [cited 2020 Dec 10]. p. 121–3.
- 359 Available from:
- http://www.ncbi.nlm.nih.gov/pubmed/25674993%0Ahttp://www.pubmedcentral.nih.
- gov/articlerender.fcgi?artid=PMC4584687
- 5. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented
- infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2).
- 364 Science (80-) [Internet]. 2020 May 1 [cited 2020 Dec 10];368(6490):489–93.
- Available from: https://science.sciencemag.org/content/368/6490/489
- 6. Gamado KM, Streftaris G, Zachary S. Modelling under-reporting in epidemics. J
- Math Biol. 2014;69(3):737–65.
- 368 7. Adalja AA, Toner E, Inglesby T V. Priorities for the US Health Community
- Responding to COVID-19. JAMA [Internet]. 2020 Apr 14 [cited 2020 Dec
- 10];323(14):1343. Available from:
- https://jamanetwork.com/journals/jama/fullarticle/2762690
- 8. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio
- 373 C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'.
- Nature [Internet]. 2020 Aug 20 [cited 2020 Dec 10];584(7821):425–9. Available
- from: http://www.nature.com/articles/s41586-020-2488-1
- 9. Dalziel BD, Lau MSY, Tiffany A, McClelland A, Zelner J, Bliss JR, et al.
- Unreported cases in the 2014-2016 Ebola epidemic: Spatiotemporal variation, and
- implications for estimating transmission. PLoS Negl Trop Dis.

2018;12(1):e0006161. 379 10. Enserink M. How many Ebola cases are there really? Sci Now [Internet]. 2014;4. 380 Available from: 381 http://search.ebscohost.com/login.aspx?direct=true&db=a2h&AN=99172119&site=e 382 host-live 383 11. Rivers C, Chretien J-P, Riley S, Pavlin JA, Woodward A, Brett-Major D, et al. Using 384 "outbreak science" to strengthen the use of models during epidemics. Nat Commun 385 [Internet]. 2019 Dec 15 [cited 2020 Dec 10];10(1):3102. Available from: 386 http://www.nature.com/articles/s41467-019-11067-2 387 12. Enserink M, Kupferschmidt K. Mathematics of life and death: How disease models 388 shape national shutdowns and other pandemic policies. Science (80-) [Internet]. 389 2020 Mar 25 [cited 2020 Dec 10]; Available from: 390 https://www.sciencemag.org/news/2020/03/mathematics-life-and-death-how-391 disease-models-shape-national-shutdowns-and-other 392 13. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. 393 Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. 394 Nature [Internet]. 2020 Aug 13 [cited 2020 Dec 10];584(7820):257–61. Available 395

from: http://www.nature.com/articles/s41586-020-2405-7

https://doi.org/10.25561/77482.

396

397

398

399

400

14.

mortality and healthcare demand. 2020 [cited 2020 Dec 10]; Available from:

Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al.

Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19

- 15. Xia Z-Q, Wang S-F, Li S-L, Huang L-Y, Zhang W-Y, Sun G-Q, et al. Modeling the
- transmission dynamics of Ebola virus disease in Liberia. Sci Rep [Internet]. 2015
- 403 Nov 8 [cited 2020 Dec 11];5(1):13857. Available from:
- http://www.nature.com/articles/srep13857
- 16. Heesterbeek JAP, Dietz K. The concept of R<sub>o</sub> in epidemic theory. Stat Neerl
- 406 [Internet]. 1996 Mar 1 [cited 2020 Dec 11];50(1):89–110. Available from:
- http://doi.wiley.com/10.1111/j.1467-9574.1996.tb01482.x
- 408 17. Meltzer MI, Atkins CY, Santibanez S, Knust B, Petersen BW, Ervin ED, et al.
- Estimating the Future Number of Cases in the Ebola Epidemic Liberia and Sierra
- Leone, 2014–2015 [Internet]. MMWR. Morbidity and mortality weekly report. 2014
- [cited 2020 Dec 11]. Available from: http://stacks.cdc.gov/view/cdc/24900
- 18. Knock ES, Whittles LK, Lees JA, Perez-Guzman PN, Verity R, FitzJohn RG, et al.
- Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2
- epidemic in England. Sci Transl Med [Internet]. 2021 Jun 22 [cited 2021 Jun 30];
- 415 Available from:
- https://stm.sciencemag.org/content/early/2021/06/21/scitranslmed.abg4262.abstract
- 417 19. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing
- Optimal Target Populations for Influenza Vaccination Programmes: An Evidence
- Synthesis and Modelling Study. Leung GM, editor. PLoS Med [Internet]. 2013 Oct 8
- 420 [cited 2021 Jul 8];10(10):e1001527. Available from:
- https://dx.plos.org/10.1371/journal.pmed.1001527
- 20. Diekmann O, Heesterbeek JAP, Metz JAJ. On the definition and the computation of

the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. J Math Biol. 1990;28(4):365–82.

- Diekmann O, Heesterbeek JAP, Roberts MG. The construction of next-generation matrices for compartmental epidemic models. J R Soc Interface. 2010;7(47):873–85.
- 427 22. Grantz KH, Lee EC, D'Agostino McGowan L, Lee KH, Metcalf CJE, Gurley ES, et 428 al. Maximizing and evaluating the impact of test-trace-isolate programs: A modeling 429 study. PLOS Med [Internet]. 2021 Apr 30 [cited 2021 Dec 3];18(4):e1003585.
- Available from: https://dx.plos.org/10.1371/journal.pmed.1003585

ce=1

- WHO. EMERGENCY GUIDELINE Implementation and management of contact tracing for Ebola virus disease [Internet]. 2015 [cited 2020 Dec 10]. Available from:

  https://apps.who.int/iris/bitstream/handle/10665/185258/WHO\_EVD\_Guidance\_Co
  ntact\_15.1\_eng.pdf;jsessionid=1BA73A77042B8EA4BE60F9A971E37D46?sequen
- NHS. If you're told to self-isolate by NHS Test and Trace NHS [Internet]. 2020 [cited 2020 Dec 10]. Available from: https://www.nhs.uk/conditions/coronavirus-covid-19/testing-and-tracing/nhs-test-and-trace-if-youve-been-in-contact-with-a-person-who-has-coronavirus/
- Verrall A. Rapid Audit of Contact Tracing for Covid-19 in New Zealand [Internet].

  2020 [cited 2020 Dec 14]. Available from:
- https://apo.org.au/sites/default/files/resource-files/2020-04/apo-nid303350.pdf
- Center for connected learning and computer-based modeling. NetLogo [Internet].
   1999. Available from: http//ccl.northwestern.edu/NetLogo/

27. Baker MG, Kvalsvig A, Verrall AJ, Telfar-Barnard L, Wilson N. New Zealand's 445 elimination strategy for the COVID-19 pandemic and what is required to make it 446 work [Internet]. Vol. 133, New Zealand Medical Journal. 2020 [cited 2020 Dec 14]. 447 p. 10-4. Available from: https://www.nzma.org.nz/journal-articles/new-zealands-448 elimination-strategy-for-the-covid-19-pandemic-and-what-is-required-to-make-it-449 work 450 Jefferies S, French N, Gilkison C, Graham G, Hope V, Marshall J, et al. COVID-19 28. 451 in New Zealand and the impact of the national response: a descriptive 452 epidemiological study. Lancet Public Heal [Internet]. 2020 [cited 2020 Dec 453 14];5(11):e612–23. Available from: www.thelancet.com/ 454 29. James A, Plank MJ, Hendy S, Binny R, Lustig A, Steyn N, et al. Successful contact 455 tracing systems for COVID-19 rely on effective quarantine and isolation 4 August 456 2020. [cited 2020 Dec 14]; Available from: 457 https://doi.org/10.1101/2020.06.10.20125013 458 30. New Zealand Ministry of Health. COVID-19: Souce of cases. 2020. 459 31. Dixon MG, Taylor MM, Dee J, Hakim A, Cantey P, Lim T, et al. Contact Tracing 460 Activities during the Ebola Virus Disease Epidemic in Kindia and Faranah, Guinea, 461 2014 - Volume 21, Number 11—November 2015 - Emerging Infectious Diseases 462 journal - CDC. [cited 2020 Dec 14]; Available from: 463 https://wwwnc.cdc.gov/eid/article/21/11/15-0684 article 464

Swanson KC, Altare C, Wesseh CS, Nyenswah T, Ahmed T, Eyal N, et al. Contact

tracing performance during the Ebola epidemic in Liberia, 2014-2015. Althouse B,

32.

465

editor. PLoS Negl Trop Dis [Internet]. 2018 Sep 12 [cited 2020 Dec 467 14];12(9):e0006762. Available from: 468 https://dx.plos.org/10.1371/journal.pntd.0006762 469 33. Unwin HJT, Baguelin M. MissingCases. 2020; 470 34. WHO. No early end to the Ebola outbreak. 2014. 471 35. Centers for Disease Control and Prevention (CDC). Updating the Estimates of the 472 Future Number of Cases in the Ebola Epidemic—Liberia, Sierra Leone, and Guinea, 473 2014–2015 | Ebola (Ebola Virus Disease) | CDC [Internet]. 2020 [cited 2020 Dec 474 15]. Available from: https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-475 africa/estimating-future-cases/december-2014.html 476 36. Gignoux E, Idowu R, Bawo L, Hurum L, Sprecher A, Bastard M, et al. Use of 477 Capture–Recapture to Estimate underreporting of Ebola Virus disease, Montserrado 478 County, Liberia [Internet]. Vol. 21, Emerging Infectious Diseases. 2015 [cited 2020] 479 Dec 15]. p. 2265–7. Available from: http://wwwnc.cdc.gov/eid/article/21/12/15-480 0756 article.htm 481




Figure 1: Potential pathways for a three-state model of Ebola surveillance (ND, AS, NAS). R is the effective reproduction number,  $\alpha$  is the scaling of the reproduction number due to active surveillance (rapid isolation upon symptom onset),  $\varphi$  is the proportion of contacts recalled and reported by a case,  $\gamma$  is the proportion of contacts actively under surveillance, and  $\pi$  is the proportion of cases detected or "re-captured" by community surveillance. We assume that all cases under active surveillance are detected. The coloring and shape of the end points of the paths are described as follows: red circle - any case that was not detected (so cannot be under active surveillance), purple circle - an eventually detected case that was not under active surveillance at the time of symptom onset (e.g. a contact of an earlier case lost to follow-up or who refused follow-up), purple square: a detected case that was under active surveillance at the time of symptom onset (e.g. a contact of a previously detected case, correctly recalled and reported, and under surveillance).




Figure 2: Directed acyclic graph showing the functional relationships of the surveillance model and the ratios observed in the surveillance. The blue nodes represent the parameters of the model that we want to infer ( is the proportion of cases detected or "re-captured" by community surveillance; is the proportion of contacts actively under surveillance; is the proportion of contacts recalled by a case and is the scaling of reproduction number due to active surveillance (rapid isolation upon symptom onset)). The green terminal nodes are the potentially observable data ( is the ratio of cases who were contacts but not under surveillance versus the cases who were contacts and under surveillance; and as the ratio of de novo cases versus detected cases that were contacts and under surveillance. The white nodes are our calculated terms ( is the proportion of cases that are not detected; and relates the proportion of not detected cases to the other two types of cases). The arrows show the direction of the dependence.




Figure 3: Comparison of NGM estimate of proportion of infections not detected against simulated proportion for 3 scenarios. The error bars parallel to the x-axis depict the 95% CrIs from the NGM estimates. Figure 3A shows a scenario with contact tracing like SARS-CoV-2 in NZ, Figure 3B shows a scenario with contact tracing like Ebola from Guinea and Figure 3C shows a scenario in which contact tracing starts like the Ebola scenario and improves to be like the SARS-CoV-2 scenario. The colors in Figure 3C refer to the two different time periods considered (worse contact tracing: days 100 to 500, better contact tracing days 500 to 900) in our scenarios.




Figure 4: Region of the parameter space compatible with the observed data New Zealand. Values of  $\pi$  and  $\alpha$  are sampled uniformly from  $[0,1]^2$ . The dots show our feasible samples with the color indicating the proportion of not detected infections.




Figure 5: Region of the parameter space compatible with the observed data for the two scenarios in Guinea. Values of and are sampled uniformly from . The dots show our feasible samples with the color indicating the proportion of not detected infections.

Table 1: Estimates of the parameters for SARS-CoV-2 in New Zealand

| Parameter | Description   | Median estimates (95% CrI) |  |
|-----------|---|----------------------------|--|
|           | Proportion of cases detected in the community       | 84.8% (61.9, 99.2)         |  |
|           | Scaling of the reproduction number for traced cases | 50.2% (4.28, 98.3)         |  |
|           | Proportion of contacts recalled                     | 91.9% (86.6, 99.5)         |  |
|           | Proportion of contacts under active surveillance    | 77.2% (71.2, 79.9)         |  |
|           | Proportion of infections not detected               | 5.26% (0.243, 16.0)        |  |

Table 2: Estimates of the parameters for Ebola in Guinea

|            |  | Median estimates (95% CrI) |                            |
|------------|--|----------------------------|----------------------------|
| Parameter  | Description  | Scenario 1 ( $r_1 = 0.2$ ) | Scenario 2 ( $r_1 = 0.5$ ) |
| $r_2$      | Ratio of de novo cases versus detected cases that were contacts and under surveillance | 2.85                       | 3.57                       |
| $\pi$      | Proportion of cases detected in the community  | 54.0% (10.1, 97.8)         | 57.03% (16.0, 97.9)        |
| α          | Scaling of the reproduction number for traced cases                                    | 49.8% (2.51, 97.4)         | 49.7% (2.54, 97.6)         |
| φ          | Proportion of contacts recalled  | 35.7% (29.8, 83.1)         | 38.6% (29.9, 89.1)         |
| γ          | Proportion of contacts under active surveillance                                       | 73.0% (33.6, 83.0)         | 53.3% (24.2, 66.2)         |
| $\mu_{ND}$ | Proportion of infections not detected  | 39.0% (1.69, 87.0)         | 37.7% (1.70, 80.9)         |